Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy.

CONCLUSIONS: Tremelimumab monotherapy demonstrated clinical activity and durable responses in patients with metastatic urothelial carcinoma. This study is the first in which CR has been observed with tremelimumab as a single agent in urothelial carcinoma.
PMID: 31801732 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 3, 2019 Category: Cancer & Oncology Authors: Sharma P, Sohn J, Shin SJ, Oh DY, Keam B, Lee HJ, Gizzi M, Kalinka E, de Vos FYFL, Ruscica D, Ferro S, Xiao F, Baverel P, Chen CC, Asubonteng K, Morsli N, Dirix L Tags: Clin Cancer Res Source Type: research